CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis
Regeneron and Sanofi announced the EMA's CHMP has adopted a positive opinion for Dupixent® (dupilumab) in a third indication. The CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP.
. September 20, 2019